Imv Investor Relations Material
Latest events
Q4 2022
Imv
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Imv Inc
Access all reports
IMV Inc. operates as a clinical-stage immuno-oncology company. Its lead candidate is DPX-Survivac, which is in Phase II trial for the treatment of recurrent ovarian cancer, as well as in Phase I/II trial for the treatment of advanced cancers; and developing a combination therapy regimen with checkpoint inhibitor. The company's product candidates also include DPX-E7, which is in Phase I/II trial for the treatment of human papillomavirus associated cancers; and DIANOVA for the treatment of solid tumors. In addition, it is developing DPX-RSV that has completed preclinical trials for used in lung cancer; and DPX-COPD vaccine to treat chronic obstructive pulmonary disease. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
IMV
Country
🇺🇸 United States